Wall Street Signals: Tapping Into New Multi Billion $ Markets Is Expected To Result In $100's Of Thousands In New Revenue/Sales In 2018

Tapping Into New Multi Billion $ Markets Is Expected To Result In $100's Of Thousands In New Revenue/Sales In 2018

Summary

Re-Branding The Corporate Structure.
New Multi Billion $ Markets Opening Up.
Markets Have Rapid CAGR's.
2018 Catalysts Are Anticipated To Reap Big Rewards.
Pressure BioSciences, Inc. (PBIO) Has been making progress toward greater things for quite a while. In 2017 that changed significantly with Agreements, Acquisitions, New and Updated Software, and a Redesigned/Upgraded Flagship Instrument.
This will move the company forward in 2018 like no other year. As they embark on and segue into newer markets that are Multi Billion $ sales & revenue producing industries/spaces, PBIO is now poised to take advantage.
It is expected these new markets will bring $100's of thousands of new sales/revenues into the company. 
  • Protein Based Drugs and Biotherapeutics
  • Bio Pharma Manufacturing
  • <GMP> Good Manufacturing Practice Capabilities
  • Compliance
  • CBD Oils
  • Paints
  • Cosmetics
  • Clean Foods & More
How about we investigate a portion of the impetuses and foundations for this new development and excitment. 
To start, PBIO will extend universally (Center for Excellence in China) in Asia, the Far East, and Europe. 
They additionally have expanded their Sales Staff
The Redesigned & Upgraded 2320EXTREME is now Computer Operated and Run. It now adaptable to other applications etc. This is part of the Main (Existing) Group of the company, or shall we say the initial or First Group Of PBIO
  • Group I - "Research & Product Services"
As of now PBIO has put instruments in more than 300 areas all around. Their customer gathering of more than 180 is impessive. A portion of these present customers will return to PBIO for the Newest 2320EXTREME (One Multi Billion $ International customer has just obtained four (4) They envision numerous new customers because of the more extensive scope of aaditional stages, forms and new programming.
  • Group II - "Bio Pharma Manufacturing"
The move into Protein Based Drugs, Therapeutics, Bio Pharma has been met with superior to anything expected outcomes. They have one New Contract and two different request as of now, in a matter of months subsequent to securing Barofold's innovation/stage. This has been proficient with no advertising what so everThe organization is to a great degree pleaseed with this.
These agreements should come in stages, the main contract is a five figure one, it should bring about a moment stage, and that agreement is foreseen to bring six figures. 
A noteworthy reward is that these organizations will do their R and D and so forth in/at PBIO Facilities. This means PBIO approaches measure and take after as the procedure results and is progressing. 
PreEMT Platform is the key for the early achievement. You can Also add to that ISS, Inc. A Two Year (2) Agreement for their Pressure Optical Cell joined with PBIO's "The Hub", was declared and as indicated by the understanding, both arrangement to Cross Sell every others items and use the others Client Data Base-Email Lists. ISS has the bigger of the two, substantially bigger.
Generally this Second Group could take into consideration PBIO to be the Only Company in the World to have the capacity to approach and address Bip Pharma organizations, that are delivering Protein Based Drugs and using PBIO's Platforms, adding them to their assembling procedure improving a far protein durg, with higher quality, more secure, and conceivably taking into consideration that medication to be discharged and go available, when before it might not have. The potential is dumbfounding.
Royalties might be acknowledged if any organization finishes the procedure of another medication endorsement and is fruitful in picking up FDA freedom to take the item to advertise. 
PBIO Plans to Target Protein Based Biotherapeutical and Bio Pharma organizations, colleges and labs worlwide.
The Second New Group added to the corporate structure or now the Third Group, is the Ultra Shear Technology Group or <UST Group>.
  • Group III - Ultra Shear Technology-Platform
This new gathering is similarly as energizing as the other new gathering. Maybe more so. 
<UST> innovation or the stage fundamentally shears emulsions into the smallest of extents, along these lines making Nano-Emulsions. 
These Nano Emulsions are so little the procedure or stage takes into consideration water and oil to blend or have a higher or better rate of combining without isolating. 
Consider CBD Oils, which is picking up piece of the overall industry because of their therapeutic highlights. The issue is while they are great, <UST> could empower them to be obviously better. Oil and Water don't blend recollect? The human body is 60% water. There for the ingestion rate of the CDB Oil is low 10-20% tops. <UST> ought to have the capacity to amplify the absorpton rate or %, expanding it to 80%, Perhaps higher. 
That could mean lower doses, which thusly could bring about a cost reserve funds to the customer/understanding, spreading that medicine out longer. 
Paints-Imagine purchasing paint, utilize it, store for a long time, haul out, fly off cover and plunge in, no strirring, blending, shaking, great as the very beginning. <UST> could do this. 
Clean Foods-Remove all poisons, additives, man made, and have a more extended timeframe of realistic usability? <UST>
As should be obvious things are warming up, pushing ahead quickly. Snappier than they anticipated. Furthermore, I didn't specify accomplishing over $2,000,000 in Sales with One Sales Rep!! Nine Consecutive Quarters of Growth/Increased Sales/Revenues/Product Services. Resigning close 50% of the obligation $6.39 Million Converting it to Equity. That relatively paid for the whole Barofold, Inc. acquistion. Obviously the Private Investors or most have confidence in the organization and future looking forward. 
That is the thing that we don't comprehend, with this, value plunges, needs volume. Numerous outside, outsider sources think and have expressed PBIO is way underestimated, exchanging awfully low for what they have and what is coming. They figure it ought to be in any event $5.00 and with substantially more volume. 
We think it is a long play with all that is going on and coming into view. Short Term gains are possible, as has been proven in the past.
Take the time, do your own research, you can visit https://www.yahoofinance.com or https://www.otcmarkets.com
Robert E. Kreh – Principal
Small Cap Solutions, LLC

(443) 567-2609

(OTCQB:PBIO) Disclaimer:
You are accepting this since you have asked for the data contained in this email, and additionally have communicated an intrigue as of late, or in the past to be incorporated into such messages. And additionally have asked for data/news/refreshes for Pressure BioSciences, Inc. This profile has been ordered by Small Cap Solutions, LLC in light of data from the organization accepted to be valid/verifiable. This profile isn't ensured, neither inferred, nor in composing, with regards to the exactness and culmination of substance, and arranged for data purposes as it were. All things considered, this profile may contain forward achieving articulations, as characterized in the Private Securities Litigation Act of 1995. Genuine outcomes could contrast tangibly from the announcements either communicated or inferred thus. Imminent speculators are encouraged to survey the Company's intermittent filings with the Securities and Exchange Commission or at otcmarkrts.comyahoofinance.com - Small Cap Solutions, LLC has received ($3,000.00) cash from Value Quest, Inc. for investor relations services rendered for Pressure BioSciences, Inc. Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.